Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
Status:
Completed
Trial end date:
2020-12-20
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to evaluate the efficacy and safety of the combination
therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA)
standard of care. In this clinical trial, rtPA will be injected intravenously using an
infusion device. If reperfusion is not occur in spite of rtPA therapy, endovascular therapy
can be performed.